Hosted on MSN5d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media ...
In the ASCENT Phase 3 clinical trial of sacituzumab govitecan, a topo-1 ADC, the ORR with ... clinical pharmacodynamic STING activation data related to XMT-2056; Mersana’s collaborations with ...
This performance surpasses expectations and suggests potential efficacy in breast cancer patients who have already undergone topo-1 ADC treatments. Despite a significant drop in Mersana’s stock ...
an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback